Earnings Call · Q3 FY2022·2022-08-04

Q3 22EPS -33.33%·Rev n/aQ2 22EPS +100.00%*·Rev n/aQ1 22EPS -3.45%·Rev n/aQ4 21EPS -100.00%*·Rev n/a⚠ consensus missing

ARROWHEAD PHARMACEUTICALS, INC. ARWR

Vince Anzalone — Vice President

Christopher Anzalone — President and Chief Executive Officer

Javier San Martin — Chief Medical Officer

James Hamilton — Senior Vice President, Research and Development

Ken Myszkowski — Chief Financial Officer

−0.4%1d on move date−0.2% vs SPY3d−1.5%5d−1.1%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ARWR calls or request research access.

More ARWR calls Browse calls Request research access